Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijantimicag.2014.08.002 http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2014.08.002 C4417356!4417356!25261158     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25261158&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Antimicrob+Agents 2014 ; 44 (5): 387-95 Nephropedia Template TP {{tp|p=25261158|t=2014. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci |pdf=|usr=}}{{25261158}} gab.com Text Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci JO: Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=25261158 #FOAvip Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE. Twit Text FOAVip Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci ????Int J Antimicrob Agents http://www.kidney.de/pget.php?&tw=1&pmid=25261158 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25261158 #FOAvip English Wikipedia <ref>{{Cite pmid|25261158}}</ref> Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci #MMPMID25261158 Munita JM; Murray BE; Arias CA Int J Antimicrob Agents 2014[Nov]; 44 (5): 387-95 PMID25261158show ga Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE. äDaptomycin for the treatment of bacteraemia due to vancomycin-resistan(epmc).pdf DeepDyve Pubget Overpricing